Inhibiting early activation of tissue nuclear factor-κB and nuclear factor interleukin 6 with (1→3)-β-D-glucan increases long-term survival in polymicrobial sepsis

Surgery

Volumn 126, Issue 1, 1999, Pages 54-65

  Williams, David L ^a   Ha, Tuanzhu ^a   Li, Chaunfu ^a   Kalbfleisch, John H ^a   Laffan, John J ^a   Ferguson, Donald A ^a  

^a East Tennessee State University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GLUCAN; BIOLOGICAL RESPONSE MODIFIER; CYTOKINE; GLUCAN PHOSPHATE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; NUCLEAR FACTOR; POLYSACCHARIDE; SCLEROGLUCAN; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ADULT RESPIRATORY DISTRESS SYNDROME; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; IMMUNOMODULATION; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEPSIS; SUPERINFECTION; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TRANSCRIPTION INITIATION;

EID: 0032779231     PISSN: 00396060     EISSN: None     Source Type: Journal    
DOI: 10.1067/msy.1999.99058     Document Type: Article

References (55)

1. 1. Marshall J. Both the disposition and means of cure: "severe SIRS," "sterile shock" and the ongoing challenge of description. Crit Care Med 1997;25:1765-6.
2. 2. Muckart DJJ. Bhagwanjee S. American College of Chest Physicians Society of Critical Care Medicine Consensus Conference definitions of the systemic inflammatory response syndrome and allied disorders in relation to critically injured patients. Crit Care Med 1997;25:1789-95.
3. 3. Quartin AA, Schein RMH, Kett DH, Peduzzi PN. Magnitude and duration of the effect of sepsis on survival. JAMA 1997;277:1058-63.
4. 4. Bone RC. Important new findings in sepsis. JAMA 1997; 278:249.
5. 5. Martin C, Boisson C, Haccoun M, Thomachot L, Mege JL, Patterns of cytokine evolution (tumor necrosis factor-alpha and interleukin-6) after septic shock, hemorrhagic shock, and severe trauma. Crit Care Med 1997;25:1813-9.
6. 6. Salkowski CA, Detore G, Franks A, Falk MC, Vogel SN. Pulmonary and hepatic gene expression following cecal ligation and puncture: monophosphoryl lipid A prophylaxis attenuates sepsis-induced cytokine and chemokine expression and neutrophil infiltration. Infect Immun 1998;66:3569-78.
7. 7. Dellinger RP. Tumor necrosis factor in septic shock and multiple system trauma. Crit Care Med 1997;25:1771-3.
8. 8. Grau GE, Maennel DN. TNF inhibition and sepsis - sounding a cautionary note. Nature Med 1997:3:1193-5.
9. 9. Baldwin AS Jr. The NF-kappa B and I-kappa B proteins: new discoveries and insights. Annu Rev Immunol 1996;14:649-83.
10. 10. Barnes PJ. Nuclear factor-κB. Int J Biochem Cell Biol 1997:29:867-70.
11. 11. Wedel A, Ziegler-Heitbrock HW. The C/EBP family of transcription factors. Immunobiology 1995;193:171-85.
12. 12. Xia C, Cheshire JK, Patel H, Woo P. Cross-talk between transciption factors NF-kappa B and C/EBP in the transcriptional regulation of genes. Int J Biochem Cell Biol 1997; 29:1525-39.
13. 13. Schwartz MD, Moore EE, Moore FA, Shenkar R, Moine P, Haenel JB, et al. Nuclear factor-kappaB is activated in alveolar macrophages from patients with acute respiratory distress syndrome. Crit Care Med 1996;24:1285-92.
14. 14. Böhrer H, Qiu F, Zimmermann T, Zhang Y, Jilmer T, Mānnel D, et al. Role of NFκB in the mortality of sepsis. J Clin Invest 1997;100:972-85.
15. 15. Zagariya A, Mungre S, Lovis R, Birrer M, Ness S, Thimmapaya B, et al. Tumor necrosis factor alpha gene regulation: enhancement of C/EBPbeta-induced activation by c-Jun. Mol Cell Biol 1998;18:2815-24.
16. 16. Ensley HE, Tobias B, Pretus HA, McNamee RB, Jones EL, Browder IW, et al. NMR spectral analysis of a water-insoluble (1→3)-β-D-glucan isolated from Saccharomyces cerevisiae. Carbohyd Res 1994;258:307-11.
17. 17. Williams DL, Mueller A, Browder W. Glucan-based macrophage stimulators: a review of their anti-infective potential. Clin Immunother 1996;5:392-9.
18. 18. Williams DL, Sherwood ER, Browder IW, McNamee RB, Jones EL, Rakinic J, et al. Effect of glucan on neutrophil dynamics and immune function in Escherichia coli peritonitis. J Surg Res 1988;44:54-61.
19. 19. Williams DL, Browder IW, DiLuzio NR. Immunotherapeutic modification of Escherichia coli-induced experimental peritonitis and bacteremia by glucan. Surgery 1983;93:448-54.
20. 20. Browder W, Williams D, Sherwood E, McNamee R, Jones E, DiLuzio N. Synergistic effect of nonspecific immunostimulation and antibiotics in experimental peritonitis. Surgery 1987;102:206-14.
21. 21. Browder W, Williams D, Pretus H, Olivero G, Enrichens F, Mao P, et al. Beneficial effect of enhanced macrophage function in the trauma patient. Ann Surg 1990;211:605-13.
22. 22. Babineau TJ, Hackford A, Kenler A, Bistrian B, Forse RA, Fairchild PG, et al. A phase II multicenter, double-blind, randomized, placebo-controlled study of three dosages of an immunomodulator (pgg-glucan) in high-risk surgical patients. Arch Surg 1994;129:1204-10
23. 23. Babineau TJ, Marcello P, Swaits W, Kenler A, Bistrian B, Forse RA. Randomized phase I/II trial of a macrophage-specific immunomodulator (PGG-glucan) in high-risk surgical patients. Ann Surg 1994;220:601-9.
24. 24. Felippe J, Silva M, Maciel FM, Soares A, Mendes NF. Infection prevention in patients with severe multiple trauma with the immunomodulator beta 1-3 polyglucose (glucan). Surg Gynecol Obstet 1993;177:383-8.
25. 25. Baker CC, Chaudry IH, Gaines HO, Baue AE. Evaluation of factors affecting mortality rate after sepsis in a murine cecal ligation and puncture model. Surgery 1983;94:331-5.
26. 26. Ayala A, Perrin MM, Kidala JM, Ertel W, Chaudry IH. Polymicrobial sepsis selectively activates peritoneal but not alveolar macrophages to release inflammatory mediators (interleukin-1 and -6 and tumor necrosis factor). Circ Shock 1992:36:191-9.
27. 27. Williams DL, McNamee RB, Jones EL, Pretus HA, Ensley HE, Browder IW, et al. A method for the solubilization of a (1→3)-β-d-glucan isolated from Saccharomyces cerevisiae. Carbohyd Res 1991;219:203-13.
28. 28. Pretus HA, Ensley HE, McNamee RB, Jones EL, Browder IW, Williams DL. Isolation, physicochemical characterization and preclinical efficacy evaluation of soluble scleroglucan. J Pharmacol Exp Ther 1991;257:500-10.
29. 29. Lowman D, Ensley H, Williams D. Identification of phosphate substitution sites by NMR spectroscopy in a water-soluble phosphorylated (1→3)-β-D-glucan. Carbohydr Res 1998;306:559-62.
30. 30. Mueller A, Pretus H, McNamee R, Jones E, Browder I, Williams D. Comparison of the carbohydrate biological response modifiers Krestin, schizophyllan and glucan phosphate by aqueous size exclusion chromatographty with inline argon-ion multi-angle laser light scattering photometry and differential viscometry detectors. J Chromatogr 1995; 666:283-90.
31. 31. Mueller A, Rice PJ, Ensley HE, Coogan PS, Kalbfleisch JH, Kelley JL, et al. Receptor binding and internalization of water-soluble (1→3)-beta-D-glucan biologic response modifier in two monocyte/macrophage cell lines. J Immunol 1996;156:3418-25.
32. 32. Battle J, Ha T, Li C, Della Beffa V, Rice P, Kalbfleisch J, et al. Ligand binding to the (1→3)-beta-D-glucan receptor stimulates NFkB activation, but not apoptosis in U937 cells. Biochem Biophys Res Commun 1998;249:499-504.
33. 33. Williams DL, Browder IW. Development of natural product (1→3)-beta-D-glucan polymers as immune-stimulating pharmaceuticals. Polymers Adv Technol 1994;5:529-34.
34. 34. Holdeman LV, Kelley RW, Moore WEC. Anaerobic gram-negative straight, curved and helical rods. In: Krieg NR, Holt JG, editors. Manual of systematic bacteriology. Vol 1. 1st ed. Baltimore: Williams &-Wilkins; 1984. p 602-62.
35. 35. Murray RR, Baron EJ, Pfaller MA, Tenover FC, Volkers RH. Manual of clinical microbiology. 6th ed. Herndon (VA): ASM Press; 1995.
36. 36. Williams DL, Ha T, Li C, Kalbfleisch JH, Ferguson DA. Early activation of hepatic NFkB and NF-IL6 in polymicrobial sepsis correlates with bacteremia, cytokine expression and mortality. Ann Surg 1999. In press.
37. 37. Browder IW, Ha T, Li C, Kalbfleisch JH, Ferguson DA, Williams DL. Early activation of pulmonary NFkB and NF-IL6 in polymicrobial sepsis. J Trauma 1999;46:590-6.
38. 38. Williams DL, Sherwood ER, Browder IW, McNamee RB, Jones EL, Di Luzio NR. Pre-clinical safety evaluation of soluble glucan. Int J Immunopharmacol 1988;10:405-11.
39. 39. Chang CK, Llanes S, Schumer W. Effect of dexamethasone on NF-kB activation, tumor necrosis factor formation, and glucose dyshomeostasis in septic rats. J Surg Res 1997; 72:141-5.
40. 40. Matot I, Sprung CL. Corticosteroids in septic shock: resurrection of the last rites? Crit Care Med 1998;26:627-30.
41. 41. Meduri GU, Kanangat S. Glucocorticoid treatment of sepsis and acute respiratory distress syndrome: time for a critical reappraisal. Crit Care Med 1988;26:630-3.
42. 42. Bollaert PE, Charpentier C, Levy B, Debouverie M, Audibert G, Larcan A. Reversal of late septic shock with supraphysiologic doses of hydrocortisone. Crit Care Med 1998;26:645-50.
43. 43. Scheinman RI, Cogswell PC, Lofquist AK, Baldwin JAS. Role of transcriptional activation of IkBa in mediation of immunosuppression by glucocorticoids. Science 1995; 270:283-6.
44. 44. Auwardi RB, Mudge SJ, Chen CG, Power DA. Regulation of nuclear fartor kappaB by corticosteroids in rat mesangial cells. J Am Soc Nephrol 1998;9:1620-8.
45. 45. Blackwell TS, Christman JW. The role of nuclear factor-kappa B in cytokine gene regulation. Am J Respir Cell Mol Biol 1997;17:3-9.
46. 46. Onderdonk AB, Cisneros RL, Hinkson P, Ostroff G. Anti-infective effect of poly-β1-6-glucotriosyl-β1-3-glucopyranose glucan in vivo. Infect Immun 1992;60:1642-7.
47. 47. Tzianabos AO, Kasper DL, Cisneros RL, Smith RS, Onderdonk AB. Polysaccharide-mediated protection against abscess formation in experimental intra-abdominal sepsis. J Clin Pathol 1995;48:2727-31.
48. 48. Adams DS, Pero SC, Petro JB, Nathans R, Mackin WM, Wakshull E. PGG-glucan activates NF-kB - like and NF-IL-6-like transcription factor complexes in a murine monocytic cell line. J Leukocyte Biol 1997;62:865-73.
49. 49. Remick D, Manohar P, Bolgos G, Rodriguez J, Moldawer L, Wollenburg G. Blockade of tumor necrosis factor reduces lipoplysaccharide lethality, but not the lethality of cecal ligation and puncture. Shock 1995;4:89-95.
50. 50. Hara C, Kiho T, Tanaka Y, Ukai S. Anti-inflammatory activity and conformational behavior of a branched (1→3)-beta-D-glucan from an alkaline extract of Dictyophora indusiata. Carbohyd Res 1982;110:77-87.
51. 51. Hoffman OA, Olson EJ, Limper AH. Fungal β-glucans modulate macrophage release of tumor necrosis factor-α in response to bacterial lipopolysaccharide. Immunol Lett 1993;37:19-25.
52. 52. Kiho T, Sakai M, Ukai S, Hara C, Tanaka Y. Anti-inflammatory effect of the polysaccharide from the fruit bodies of Auricularia species. Carbohyd Res 1988;142:344-51.
53. 53. Masihi KN, Madaj K, Hintelmann H, Gast G, Kaneko Y. Down-regulation of tumor necrosis factor-alpha, moderate reduction of interleukin-1beta, but not interleukin-6 or interleukin-10, by glucan immunodulators curdlan sulfate and lentinan. Int J Immunopharmacol 1997;19:463-8.
54. 54. Ukai S, Kiho T, Hara C, Kuruma I, Tanaka Y. Polysaccharides in fungi, XIV: anti-inflammatory effect of the polysaccharides from the fruit bodies of several fungi. J Pharmacobio Dynamics 1983;6:983-90.
55. 55. Kulicke W-M, Letlau AI, Thielking H. Correlation between immunological activity, molar mass, and molecular structure of different (1→3)-β-D-glucans. Carbohyd Res 1997; 297:135-43.